X antigen family member 2Genealiases: CT12.2 · GAGED3 · XAGE-2 · XAGE2B
Q-omics provides the consensus-scored XAGE2 profile across patient tissues and cancer cell-line models. XAGE2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, XAGE2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, XAGE2 RNA expression shows 8,758 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where XAGE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XAGE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XAGE2 survival associations across molecular data types. XAGE2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XAGE2 RNA expression–survival associations across cancer types. High XAGE2 expression shows unfavorable associations in BLCA, HNSC, LUSC, DLBC and KIRC, but favorable associations in UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for XAGE2 RNA expression.
This table summarizes XAGE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for XAGE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XAGE2 shows lower tumor expression in KIRC, KICH, LUAD, LUSC, KIRP and BRCA. The KIRC box plot shows higher XAGE2 RNA expression in normal versus tumor tissue (log2 FC = −0.662, t-test p < 0.001).
This table shows molecular features associated with XAGE2 in patient tissues and cancer cell lines. In patient samples, XAGE2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, XAGE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
